{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Semax",
    "short_name": "Semax",
    "aliases": [],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Semax is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is reported, including in regions where it has been marketed/used clinically (often intranasal) and in gray-market contexts elsewhere. Product quality and labeling vary in non-regulated markets, increasing uncertainty."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "mechanistic_only",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Overall risk uncertainty is driven by heterogeneous clinical literature (often region-specific), variability in formulations/routes in real-world use, and limited large, modern, independently replicated trials for many claimed outcomes. Potential risks include neuropsychiatric effects, interactions with other CNS-active substances, and unknown long-term safety in adolescents.",
      "developmental_systems_of_concern": [
        "cns",
        "neurodevelopment",
        "puberty"
      ]
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Semax is a synthetic peptide based on a fragment of ACTH, developed to influence neurotrophic and neuromodulatory pathways in the brain. Published literature includes mechanistic work and clinical reports for cognition/neurologic recovery contexts, but evidence quality varies and many claims lack large, independent replication.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "",
          "unit": "",
          "min": null,
          "max": null,
          "frequency": "",
          "duration": "",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "",
        "published_date": "",
        "evidence_grade": "mechanistic_only",
        "notes": ""
      },
      {
        "id": "E2",
        "title": "[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax].",
        "source_type": "review",
        "source_id": "PMID:18379501",
        "evidence_grade": "human_observational",
        "year": 2007,
        "url": "https://pubmed.ncbi.nlm.nih.gov/18379501/",
        "notes": "Clinical literature is region-specific and heterogeneous; use for boundaries, not claims inflation."
      },
      {
        "id": "E3",
        "title": "[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].",
        "source_type": "journal_article",
        "source_id": "PMID:29798983",
        "evidence_grade": "animal",
        "year": 2018,
        "url": "https://pubmed.ncbi.nlm.nih.gov/29798983/",
        "notes": "Supports mechanism discussion only; not proof of human benefit."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Semax",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:11:26.845496+00:00",
        "change_type": "content_update",
        "summary": "Filled Semax core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed placeholder language from key descriptive fields and added a minimal evidence scaffold. No protocols/dosing/instructions added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-19T16:47:10.573738+00:00",
        "change_type": "content_update",
        "summary": "Evidence finalization: replaced PubMed placeholders with specific PMIDs/years (no instructions).",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ]
  }
}
